-transparent.png){kind=logo}
In order to investigate the effect of the pretreatment with various doses of diltiazem (DTZ) on the pharmacokinetics of indocyanine green (ICG) at steady state, especially the hepatic blood clearance due to the change of hepatic blood flow, the following experiments were carried out with ICG, a hepatic function test marker, not metabolized in liver and only excreted in bile. The intravenous bolus injection (3,780 micrograms/kg) and the constant-rate infusion (10,100 micrograms/kg/hr) of ICG into the left femoral vein were made in order to check the steady-state plasma concentration (Css of 10 micrograms/ml) of ICG at 20, 25 and 30 min. Following a 90-min washout period, the intravenous bolus injection (108, 430, 860 and 1,720 micrograms/kg) and the constant-rate infusion (108, 433, 866 and 1,730 micrograms/kg/hr) of DTZ into the right femoral vein were made and the achievement of the steady-state plasma levels (Css of 50, 200, 400 and 800 ng/ml) of DTZ were conformed at 60, 70 and 80 min. During the steady state of DTZ, the intravenous bolus injection (3,780 micrograms/kg) and the constant-rate infusion (10,200 micrograms/kg/hr) of ICG into the left femoral vein were made and also the steady-state plasma concentration of ICG was checked at 20, 25 and 30 min. The plasma concentrations of DTZ and ICG were determined using a high performance liquid chromatographic technique. At the steady state, the hepatic blood clearance of ICG was obtained from the plasma concentration and blood-to-plasma concentration ratio (RB) of ICG. The pretreatment with various doses of DTZ did not influence the plasma concentrations, RB and plasma free fraction (fp) of ICG. So the hepatic blood clearance of ICG was independent of concentration of DTZ. The hepatic blood clearance of ICG could be affected by both hepatic blood flow and hepatic intrinsic clearance. But there was no change of the hepatic blood clearance of ICG between the control and the DTZ-pretreated rats in this study. So it may be suggested that DTZ does not influence hepatic blood flow.
E H Joo, and
Y B Lee
June 1965,
Proceedings of the Society for Experimental Biology and Medicine. Society for Experimental Biology and Medicine (New York, N.Y.),
E H Joo, and
Y B Lee
June 1966,
The Journal of pharmacology and experimental therapeutics,
E H Joo, and
Y B Lee
March 1983,
Biochemical pharmacology,
E H Joo, and
Y B Lee
July 1964,
Fukuoka igaku zasshi = Hukuoka acta medica,
E H Joo, and
Y B Lee
August 1990,
British journal of clinical pharmacology,
E H Joo, and
Y B Lee
February 2014,
Minerva anestesiologica,
E H Joo, and
Y B Lee
October 1990,
British journal of clinical pharmacology,
E H Joo, and
Y B Lee
July 1992,
The Clinical investigator,
E H Joo, and
Y B Lee
May 1976,
Zeitschrift fur die gesamte innere Medizin und ihre Grenzgebiete,
E H Joo, and
Y B Lee
May 1992,
European journal of clinical investigation,
